Mylan Adds to Growing Women`s Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®
(WorldNews Netherlands)

HERTFORDSHIRE, Englandand PITTSBURGH, April 25, 2018/PRNewswire / -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, a generic version of Bayer`s Yaz® Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for use by women to prevent...